Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a share price
Ocean Biomedical Inc.
-(OCEA)
XNAS:OCEA
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation. Its business
Ocean Biomedical (OCEA) set to join the Russell 2000 Index
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index, effective after
Ocean Biomedical (OCEA) announces patent award for novel cancer immunotherapy treatment
Biopharma company Ocean Biomedical (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jack Elias has been issued a broad patent for
Ocean Biomedical announces private placement of $25 mln convertible notes
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has entered into a private placement pursuant to a securities purchase
Ocean Biomedical reports new results validating tumor suppression with anti-Chi3L1 antibody: EF Hutton raises OCEA price target to $17
Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said its scientific co-founder Jack Elias published new findings in Cancer Research, a peer-reviewed
Ocean Biomedical co-founder Jonathan Kurtis presents detailed data on malaria vaccine at conference
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical co-founder Jack Elias to receive US patent for pulmonary fibrosis treatments
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Ocean Biomedical (OCEA) announces $134 million financial backing for innovative research and IND filings
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Ocean Biomedical gets Notice of Allowance for US patent application for developing new malaria therapeutics
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company that works with research universities and medical centers for developing and commercializing their discoveries,
Ocean Biomedical (OCEA) announces new findings in relation to treatment options for Hermansky-Pudlak Syndrome
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) announced its commitment to developing viable treatment options for Hermansky-Pudlak Syndrome (HPS) on Thursday. The
Ocean Biomedical presents novel malaria therapeutic discoveries at NIH Laboratory of Malaria Vaccinology and Immunology
Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharma company that works with research universities and medical centers for developing and commercializing their
Fundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday said that Fundamental Research Corp. initiated equity analyst coverage of its stock with a “Buy”
Ocean Biomedical provides positive research data on anti-tumor pathway; stock climbs
Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) released details of discoveries that have potential applications for tumor suppression across multiple cancer pathways.
Ocean Biomedical co-founder Jake Kurtis gets new patent for novel malaria vaccine target
Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said its scientific co-founder Dr. Jonathan Kurtis received a new patent for his discovery related
Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary
The global pharmaceutical market is expected to cross $1.5 trillion this year, which represents a 4-5% annual growth over the past five
Infographic: Ocean Biomedical Inc. (OCEA) quarter ended September 30, 2022
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here’s a look at the company’s
Infographic: Ocean Biomedical Inc. (OCEA) quarter ended June 30, 2022
Ocean Biomedical, Inc. (NASDAQ: OCEA) was formed through the combination of Aesther Healthcare Acquisition Corp. with Ocean Biomedical. Here are the company’s numbers for
Ocean Biomedical slashes IPO size. Should you invest in the stock?
The biomedical industry grew at an accelerated pace in 2021 even as healthcare systems went into overdrive amidst the COVID-induced medical emergency.